The International Generic and Biosimilar medicines Association (IGBA) commends the General Assembly of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) for its adoption of a new topic focused on the harmonisation of "Framework for Determining Utility of Comparative Efficacy Studies in Biosimilar Development Programs." 

The International Generic and Biosimilar medicines Association (IGBA) remains committed to its vision of working to improve patient access to safe, effective, cost-effective, and quality-assured generic and biosimilar medicines.

The 3rd Bioequivalence Conference, co-hosted by the International Generic and Biosimilar Medicines Association (IGBA) and Medicines for Europe, concluded today at the Hilton Amsterdam Airport Schiphol Hotel, The Netherlands. This landmark event brought together experts from regulatory authorities, industry, and academia to discuss the evolving bioequivalence landscape and its critical role in improving global access to medicines.